Biogen Inc (NASDAQ: BIIB) has reported earnings for its fourth fiscal quarter (ending December 31) of $1.83 versus $1.72 for the same period a year ago — an increase of 6%. Relative to the consensus estimate of $3.36, this was a shortfall of $-1.53. E.P.S. were $11.21 for the latest four quarters through December 31 versus $8.02 for the same period a year ago — an increase of 40%.
Recent Price Action
On 2/12/25, Biogen Inc (NASDAQ: BIIB) stock declined by -4.3%, closing at $133.43. Moreover, trading volume in this decline was exceptionally high at 245% of normal. The stock has declined -6.4% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Biogen has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Biogen has a good Appreciation Score of 79 but a very low Power Rating of 7, leading to the Negative Value Trend Rating.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment